Israel to start COVID-19 vaccine human trials on Nov. 1

JERUSALEM (Reuters) - Israel will begin human trials for a potential COVID-19 vaccine developed by a research institute overseen by the Defence Ministry on Nov. 1 after receiving regulatory approval, the ministry said on Sunday. The Israel Institute for Biological Research (IIBR) began animal trials for its 'BriLife' vaccine in March

Reuters October 26, 2020 01:10:41 IST
Israel to start COVID-19 vaccine human trials on Nov. 1

COVID-19 vaccine human trials on Nov. 1" src="https://images.firstpost.com/wp-content/uploads/reuters/10-2020/26/2020-10-25T182727Z_1_LYNXMPEG9O0IK_RTROPTP_2_ISRAEL-POLITICS-BUDGET.jpg" alt="Israel to start COVID19 vaccine human trials on Nov 1" width="300" height="225" />

JERUSALEM (Reuters) - Israel will begin human trials for a potential COVID-19 vaccine developed by a research institute overseen by the Defence Ministry on Nov. 1 after receiving regulatory approval, the ministry said on Sunday.

The Israel Institute for Biological Research (IIBR) began animal trials for its "BriLife" vaccine in March. The Health Ministry and an oversight committee have now given the green light to take it to the next stage.

Eighty volunteers aged between 18 and 55 will be monitored for three weeks to see if virus antibodies develop, the ministry said in a statement. A second phase, expected to begin in December, will involve 960 people over the age of 18.

Should those succeed, a third, large-scale phase with 30,000 volunteers is scheduled for April/May. If successful, the vaccine may then be approved for mass use.

The vaccine, the ministry said, has already tested well on a number of animal models and the IIBR has produced more than 25,000 doses for the first and second phases of the clinical trials.

"Our final goal is 15 million rations for the residents of the State of Israel and for our close neighbours," said IIBR Director Shmuel Shapira.

There are no internationally approved vaccines yet, but several are in advanced trials, including from Pfizer Inc, Johnson & Johnson, AstraZeneca Plc and Moderna.

Israel, with a population of 9 million, has begun easing a second nationwide coronavirus lockdown after a steady decline in the rate of daily infections. The country saw 692 new cases on Saturday - down from a peak of more than 9,000 several weeks ago. It has reported 2,372 deaths from the pandemic.

(Reporting by Ari Rabinovitch; Editing by Nick Macfie)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

U.S. data suggest economic recovery may be weakening
Business

U.S. data suggest economic recovery may be weakening

By Howard Schneider WASHINGTON (Reuters) - The explosive surge in U.S. coronavirus cases this fall has left a question hanging: When will the economy take its own turn for the worse

Fed, ECB heads give COVID-19 vaccine cautious welcome
Business

Fed, ECB heads give COVID-19 vaccine cautious welcome

FRANKFURT/WASHINGTON (Reuters) - The heads of the Federal Reserve and the European Central Bank welcomed the encouraging results in trials of a vaccine candidate for the novel coronavirus but stressed that the economic outlook will remain uncertain. Fed chair Jay Powell and ECB President Christine Lagarde said the economy was still in for a tough time even if the development of a potential vaccine by U.S. drugmaker Pfizer and German partner BioNTech SE was reason for some optimism further ahead

India's October fuel demand marks first year-on-year gain in 8 months
Business

India's October fuel demand marks first year-on-year gain in 8 months

By Sumita Layek (Reuters) - India's fuel consumption in October registered its first year-on-year increase since February, as slowing coronavirus cases and increased mobility accelerated an economic recovery, data showed on Thursday.